Summary of Consolidated Financial Statements
for the First Nine Months of Fiscal Year Ending December 31, 2023
[Japanese GAAP]
November 14, 2023
Company Name

SymBio Pharmaceuticals Limited

Listing: Tokyo Stock Exchange

Securities Code4582

URL: https://www.symbiopharma.com/

Representative

Representative Director,
President and Chief Executive Officer

Fuminori Yoshida

Contact Person

Executive Corporate Officer andChief Financial Officer

Takaaki Fukushima

TEL +81-3-5472-1125

Date of Dividend
Payment (plan)–

Scheduled Date to File Quarterly November 14, 2023
ReportSupplementary materials for the quarterly financial statements:

Yes ・ No

Holding of quarterly earnings performance review:

Yes ・ No

(Amounts of less than one million yen are rounded down.)
1. Business Results for the First Nine Months of FY 2023 (January 1, 2023 to September 30, 2023)(1) Consolidated Operating Results (cumulative)(Percentages indicate year-on-year changes.)
Net Sales
Q3 FY 2023
Q3 FY 2022

Operating Profit

Millions of yen

%

4,421
7,355

(Note) Comprehensive income:Millions of yen(39.9)–

Earnings per Share

%

(283)
1,588

Q3 FY 2023
Q3 FY 2022

Profit attributable toowners of parent

Ordinary Profit––

Millions of yen

%

(156)
1,843

Millions of yen

–
–

(788)
1,555

(790) million yen [ – %]1,555 million yen [ – %]Diluted Earnings per Share
Yen

Yen

Q3 FY 2023
(19.89)–Q3 FY 2022
40.00
39.43
(Note) Diluted earnings per share is not stated due to recording of a net loss per share, despite the potential dilution of shares.
(2) Consolidated Financial Position
Total Assets
Millions of yen

Q3 FY 2023 (as of September 30, 2023)
FY 2022 (as of December 31, 2022)(Reference) Shareholders’ equity:

Net Assets

8,451
10,433Equity Ratio

Millions of yen

%

7.678
8,506

Q3 FY 2023 (as of September 30, 2023)
FY 2022 (as of December 31, 2022)

87.7
77.6

7,410 million yen
8,094 million yen

2. Dividends
Annual Dividend per ShareFY 2022
FY 2023
FY 2023 (Forecast)

1st Quarter
Yen

–
–

2nd Quarter
Yen

3rd Quarter
Yen

Fiscal Year End
Yen

0.00

0.00

0.00

–

0.00

0.00

0.00

–

(Note) Revision of dividend forecasts most recently announced: Yes ・ No

Full Year
Yen

%

–
–

3. Earnings Forecasts for FY 2023 (January 1, 2023 to December 31, 2023)
Operating Profit(Loss)Net Sales
Full Year

Millions of yen

5,603% Millions of yen(44.0)

Ordinary Profit(Loss)% Millions of yen(680)(Percentages indicate year-on-year changes.)
Profit (Loss)
Earnings (Loss) per
attributable toShareowners of parent–% Millions of yen

(549)

–

(1,291)%–

Yen(32.53)(Note) Revision of earnings forecasts most recently announced: Yes ・ No
Notes:(1) Changes in significant subsidiaries during the period:(Transfer of specified subsidiary accompanying a change in the scope of consolidation)
New: None
Removed: None

Yes ・ No

(2) Application of special accounting treatment in preparing the quarterly financial statements: Yes ・ No
(3) Changes in accounting policies, changes in accounting estimates and restatements after error corrections(a) Changes in accounting policies due to revision of accounting standards:

Yes ・ No(b) Changes in accounting policies due to other reasons:Yes ・ No(c) Changes in accounting estimates:

Yes ・ No(d) Restatements after error corrections:

Yes ・ No

(4) Number of issued shares (common stock)(i) Total number of issued shares at the end of
the period (including treasury shares)(ii) Total number of treasury shares at the endof the period(iii) Average number of shares during theperiod (cumulative)

Q3 FY 2023

39,858,356 shares

FY 2022

39,603,606 shares

Q3 FY 2023

86,919 shares

FY 2022

85,268 shares

Q3 FY 2023

39,659,960 shares

Q3 FY 2022

38,893,556 shares* Summary of the quarterly financial statements is not subject to quarterly reviews by certified public accountants or accounting
corporations.
* Explanation regarding the appropriate use of earnings forecasts and other matters
All forecasts presented in this document, including earnings forecasts, are based on the information currently available to theCompany and assumptions determined by the Company to be reasonable. Actual results may differ substantially from these
forecasts due to various factors. Regarding the assumptions on which the Company’s earnings forecasts are based and their usage,
please refer to “1. Qualitative Information on Quarterly Financial Results (3) Explanation of consolidated earnings forecast andother forward-looking information” on Page 4 of the Appendix.

Appendix
Index
1. Qualitative Information on Quarterly Financial Results ........................................................................................................................ 2(1) Business results ................................................................................................................................................................................ 2(2) Summary of financial position ......................................................................................................................................................... 4(3) Explanation of consolidated earnings forecasts and other forward-looking information ................................................................. 4
2. Quarterly Consolidated Financial Statements and Primary Notes ......................................................................................................... 5(1) Quarterly consolidated balance sheet ............................................................................................................................................... 5(2) Quarterly consolidated statement of income and consolidated statement of comprehensive income ............................................... 7
Quarterly consolidated statement of income for the first nine months of FY 2023 .......................................................................... 7
Quarterly consolidated statement of comprehensive income for the first nine months of FY 2023 ................................................. 8(3) Notes to quarterly consolidated financial statements ....................................................................................................................... 9(Notes to going concern assumptions).............................................................................................................................................. 9(Notes in case of significant changes to shareholders’ equity) ......................................................................................................... 9(Accounting policy changes) ............................................................................................................................................................ 9(Significant subsequent events) ........................................................................................................................................................ 9―1―

1. Qualitative Information on Quarterly Financial Results(1) Business results
Progress of business of the Company and subsidiary (“the Group”) for the first nine months of the fiscal year under review is asfollows.
(i) Business results for the period under review
In December 2020, the Group began selling TREAKISYM® (generic name: bendamustine hydrochloride or bendamustinehydrochloride hydrate) through its own sales organization.
The Group has established a highly productive salesforce consisting of qualified medical representatives nationwide. As our
medical representatives have expertise in hematology and are deployed nationally, they are capable of effectively addressing the
local needs of institutions in each region in the country. To achieve nationwide distribution, we have entered into distributionagreements with Suzuken Co., Ltd. and Toho Pharmaceutical Co., Ltd. We are also working with S.D. Collabo Co., Ltd. and haveestablished two logistics centers, one in eastern and one in western Japan.
In February 2022, the Group obtained approval for a partial change to the marketing authorization of the ready-to-dilute (RTD)
liquid formulation of TREAKISYM® to add rapid infusion (RI) administration. The RTD formulation of TREAKISYM® is a liquid
formulation that eliminates the need for manual reconstitution and significantly reduces preparation time. RI administration has thefurther advantage of reducing the infusion time to 10 minutes, benefiting both patients and healthcare providers. In addition, thereduction in infusion volume of RI means a lower volume of saline solution is used.
Conversion to the RI administration has proceeded smoothly, with nearly 90% of medical institutions switching to RI
administration as of the end of September 2023.
Net sales of TREAKISYM® for Q3 totaled 4,421,104 thousand yen (-39.9% year on year). The primary factors for the year on
year decrease are the continuing downward trend in prescriptions due to COVID-19 and seasonal influenza, and the impact of genericbendamustine products which entered the market in June 2022, and the temporary sales increase in the same period last year due tothe increase in distribution inventory following the switch from freeze-dried (FD) to RTD.
Selling, general and administrative expenses totaled 3,759,453 thousand yen (-3.1% year on year). This amount includes researchand development expenses of 1,823,633 thousand yen (+16.8% year on year).
As a result, operating loss was 283,204 thousand yen (versus an operating profit of 1,588,856 thousand yen for the same period
in FY 2022) and ordinary profit was 156,382 thousand yen (versus 843,421 thousand yen for the same period in FY 2022). Loss
attributable to owners of parent amounted to 788,713 thousand yen (versus a profit attributable to owners of parent of 1,555,746
thousand yen for the same period in FY 2022) due to the reversal of deferred tax assets of 568,382 thousand yen in income taxesdeferred.
In February 2022, generic bendamustine products were approved for manufacturing and marketing in Japan. Given the potential
infringement of the patents related to TREAKISYM® in Japan which are exclusively licensed to the Company from Eagle
Pharmaceuticals, Inc (head office: New Jersey, U.S.; hereinafter “Eagle”), the Company in coordination with Eagle notified four
generic makers of potential patent infringement and, in December 2022, commenced litigation against the makers of the genericproducts, Towa Pharmaceutical Co., Ltd. (head office: Osaka) and Pfizer Japan Inc. (head office: Tokyo), seeking an injunction
against the manufacture and sale of the products and compensation for damages arising from the infringement.
Segment information has been omitted as the Group operates within a single segment, which includes the research anddevelopment, manufacturing, and marketing of pharmaceutical drugs and other related activities.
(ii) Research and development activities
During the first nine months of FY 2023, we conducted the following research and development activities.
(a) Anticancer agents: SyB L-0501 (FD formulation), SyB L-1701 (RTD formulation), and SyB L-1702 (RI administration)(generic name: bendamustine hydrochloride or bendamustine hydrochloride hydrate, trade name: TREAKISYM®)
For the RI administration, a partial change application was approved in February 2022, enabling the use of RI injection for all
approved indications of the RTD formulation in-licensed from Eagle.
The Group continues to actively conduct further research on TREAKISYM®, such as ongoing joint research with Kyoto
University, to explore new potential uses for the drug.

―2―(b) Anticancer agents: SyB L-1101 (intravenous formulation) and SyB C-1101 (oral formulation) (generic name: rigosertib
sodium)For rigosertib in-licensed from Onconova Therapeutics, Inc. (head office: Pennsylvania, U.S.), the Group is collaborating with
the University of Tokyo to conduct research to identify new potential indications or applications for the drug either alone or in
combination with other existing drugs (including bendamustine).
(c) Antiviral drug: SyB V-1901 (intravenous formulation) (generic name: brincidofovir [BCV])The Group obtained the exclusive license to brincidofovir from Chimerix Inc. (head office: North Carolina, U.S.; hereinafter“Chimerix”) in September 2019. In September 2022, Emergent BioSolutions Inc. (head office: Maryland, U.S.) completed its
acquisition of the exclusive worldwide rights to brincidofovir from Chimerix. The Group’s exclusive worldwide license to develop,
manufacture, and market BCV for all indications except orthopox virus infections (including smallpox and monkeypox) is notaffected.
The Group is prioritizing global development of BCV (primarily in Japan, the U.S., and Europe), targeting disseminatedadenovirus (AdV) infections occurring after hematopoietic stem cell transplantation. In March 2021, the Group filed an
Investigational New Drug (IND) application with the FDA to conduct a Phase II clinical trial in patients (primarily pediatric but
also adults) suffering from AdV infections. This development program was granted Fast Track designation by the FDA in April
2021. In May 2023, this study established human POC for BCV. Positive data demonstrating the efficacy of the study will bepresented orally at the 65th Annual Meeting of the American Society of Hematology in December 2023.
In addition, the Group submitted a clinical trial notification for a Phase II study in patients infected with BK virus (BKV)
infection after kidney transplantation to the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan in May 2022 and filed
another notification with the Therapeutic Goods Administration (TGA) of Australia in August 2022. BKV infection after kidneytransplantation is a disease with serious consequences for the recipient, the donor, the medical practitioner, and society, due to therisk of impaired renal function and loss of the transplanted kidney (graft loss). The investigational drug was administered to thefirst subject in December 2022. Although the trial was planned to be completed in 2025, due to delays in the accumulation of cases,
the protocol will be reviewed again with researchers.
In light of the drugs’ broad effectiveness against double-stranded DNA (dsDNA) viruses, the Group is also collaborating withleading research institutions both in Japan and overseas to study BCV’s potential use in the treatment of various other diseases.
Among dsDNA viruses, polyomaviruses are known to cause serious diseases through their infection. As existing antiviral drugs
show little efficacy, there is a high level of medical need for the development of an effective treatment. In November 2022, theGroup entered into Material Transfer Agreement with Penn State College of Medicine whereby the Group will provide BCV for
use in a non-clinical study to evaluate the efficacy of BCV in a mouse model of polyomavirus infection.
In addition to having its strong antiviral effect, BCV also is expected to have an antitumor effect, and the Group is exploring
BCV’s potential in indications such as EBV-positive lymphoma, refractory brain tumors, and other cancers, through researchcollaborations with the National Cancer Centre Singapore (NCCS) and the University of California San Francisco (UCSF) Brain
Tumor Center. In December 2022, the results of collaborative research with NCCS on the therapeutic efficacy of BCV in thetreatment of NK/T-cell lymphoma, for which no effective treatment is currently available, were presented by Dr. Jason Chan at the64th American Society of Hematology (ASH) Annual Meeting in New Orleans. Furthermore, in June 2023, the results of its
research collaboration with NCCS on BCV were presented at the 17th International Conference on Malignant Lymphoma (ICML)in Lugano, Switzerland.
The Group is also investigating the use of BCV to treat multiple sclerosis, an intractable disease that has recently been shown to
be associated with Epstein-Barr virus (EBV). In August 2022, the Company entered into a collaboration agreement with the
National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH) in the U.S., forthe transfer of materials to evaluate the antiviral effect of BCV in EBV. In March 2023, The Company has entered into a Cooperative
Research and Development Agreement (CRADA) for BCV with NINDS and in October 2023, the results of the research were
presented by Dr. Maria Chiara Monaco at the 9th Joint ECTRIMS-ACTRIMS Meeting in Milan, Italy.
The purpose of the CRADA is to verify the efficacy of BCV as an anti-viral therapeutic for EBV in the treatment of multiple
sclerosis, and to obtain necessary data with a view to future clinical trials. In April 2023, the Company entered into a CRADA with
the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH in the U.S., to investigate the efficacy of BCV in―3―the treatment of EBV associated lymphoproliferative diseases.
Some dsDNA viruses, such as herpes simplex virus type 1 (HSV1) and varicella zoster virus (VZV), are directed against cranial
nerve tissues. In recent years, research has advanced on the involvement of the reactivation of those viruses in various serious
diseases of the nervous system, including Alzheimer's disease. In December 2022, the Group entered into a Sponsored Research
Agreement with Tufts University to conduct research to evaluate the efficacy of BCV in a HSV infection model using a 3D (threedimensional) brain model established by Tufts University.
(iii) Business outside Japan
In August 2023, the Group appointed Stephane Berthier, PharmD, as CEO and President of SymBio Pharma USA, Inc., and in
September 2023, appointed Nkechi Azie, MD, to the Group management team as Global Chief Medical Officer (CMO) to further
strengthen the Group’s global development structure and make SymBio Pharma USA, Inc. the driving force for our international
clinical trials as we move forward with our global development plan for BCV.
(iv) Licensing of new drug candidates
The Group continues to evaluate promising new drug candidates for in-licensing. Through these efforts, the Group aims to create
medium-to long-term business value.

(2) Summary of financial position
Total consolidated assets as of September 31, 2023, stood at 8,451,704 thousand yen. Current assets totaled 7,894,019 thousand yen,mainly consisting of 6,114,867 thousand yen in cash and deposits, 924,782 thousand yen in accounts receivable-trade, and 333,785
thousand yen in merchandise and finished goods. Non-current assets were 557,684 thousand yen, mainly consisting of 176,346
thousand yen in deferred tax assets and 161,245 thousand yen in software.
Total liabilities were 773,057 thousand yen. Current liabilities totaled 769,152 thousand yen, mainly consisting of 587,892 thousand
yen in accounts payable-other. Non-current liabilities were 3,905 thousand yen, consisting of 3,905 thousand yen in liabilities for
retirement benefits.
Total net assets stood at 7,678,646 thousand yen. This includes 17,600,367 thousand yen in capital stock, 17,575,258 thousand yen
in capital surplus, and 268,272 thousand yen in share acquisition rights.
As a result, the equity ratio was 87.7%.

(3) Explanation of consolidated earnings forecasts and other forward-looking information
For the forecast of financial results for the year ending December 31, 2023, although the impacts of genericbendamustine products were generally in line with our expectations, the overall bendamustine market has contracted
due to a continuing decline in prescriptions and treatment delays due to seasonal influenza and COVID-19. As a result,
the Company has revised its net sales forecast downward to 5,603 million yen, which is a reduction of 874 million yen
compared to the previously announced forecast.
While continuing to prioritize R&D investment in ongoing global development of brincidofovir (“BCV”), theCompany has reduced selling, general, and administrative expenses to mitigate adverse effects of the decrease in sales.
As a result, the Company forecasts an operating loss of 680 million yen, which is a 349 million yen increase in loss
compared to the previously announced forecast, and an ordinary loss of 549 million yen, which is a 330 million yen
increase in loss compared to the previously announced forecast, despite foreign exchange valuation gains on foreign
currency denominated assets.
Income tax adjustments have increased 642 million yen as a result of careful consideration of current business environment, future
performance trends, and recoverability of deferred tax assets in the future. As a result, the net loss attributable to owners of the parent
was revised downward to 1,291 million yen, a 921 million yen increase in loss than the previously announced forecast.

―4―

2. Quarterly Consolidated Financial Statements and Primary Notes(1) Quarterly consolidated balance sheet(Unit: thousands of yen)
FY 2022(as of December 31, 2022)

Q3 FY 2023
(as of September 30, 2023)

AssetsCurrent assets
Cash and deposits
Accounts receivable–trade
Merchandise and finished goods
Semi-finished goods
Prepaid expenses
Other
Total current assets

6,282,554

6,114,867

2,084,915
293,757

924,782
333,785

175,170
209,886–
178,679

266,422

341,904

9,312,706

7,894,019

Non-current assets
Property, plant and equipment
Buildings, net

40,670212

28,339–69,00919,4036,000

Software in progress

222,204–

161,245
2,200

Total intangible assets

222,204

163,445

Investments and other assets
Deferred tax assets

744,728

176,346

Tools, furniture and fixtures, net
Construction in progress
Total property, plant and equipment
Intangible assets
Software25,616

Leasehold and guarantee deposits

84,698

192,276

Total investments and other assets

829,427
1,120,641

368,623

10,433,347

8,451,704

Total non-current assets
Total assets

557,684

Liabilities
Current liabilities
Accounts payable–trade
Accounts payable–other
Income taxes payable
Provision for product changeover
Other
Total current liabilities
Non-current liabilities
Liabilities for retirement benefits
Total non-current liabilities
Total liabilities―5―

46,633–

1,163,721
401,066

587,892
25,176

16,331
296,118–
98,681

1,923,870

769,152

3,385

3,905

3,385
1,927,255

773,057

3.905

(Unit: thousands of yen)
FY 2022(as of December 31, 2022)

Q3 FY 2023
(as of September 30, 2023)

Net assets
Shareholders’ equity
17,548,459

17,600,367

17,523,357(28,889,486)

17,575,258(27,678,199)(88,154)(88,898)

8,094,176

7,408,527

Foreign currency translation adjustment

243

1,846

Total accumulated other comprehensive income

243

1,846

Share capital
Capital surplus
Retained earnings
Treasury shares
Total shareholders’ equity
Accumulated other comprehensive income

Share acquisition rights
Total net assets
Total liabilities and net assets―6―

411,672

268,272

8,506,092

7,678,646

10,433,347

8,451,704

(2) Quarterly consolidated statement of income and consolidated statement of comprehensive income
Quarterly consolidated statement of income for the first nine months of FY 2023
Q3 FY 2022
(from January 1, 2022
to September 30, 2022)
Net sales(Unit: thousands of yen)
Q3 FY 2023
(from January 1, 2023
to September 30, 2023)
4,421,104
944,855

Gross profit

7,355,507
1,888,901
5,466,606

Selling, general and administrative expenses

3,877,749

3,759,453

Operating profit (loss)

1,588,856(283,204)95

267
167,560

Cost of sales

3,476,249

Non-operating income
Interest income
Foreign exchange gains
Other

345,287
2,925

Total non-operating income

348,309

171,538

47,59010,34645,617–

3,278
25,176

536

5,915

3,711

Non-operating expenses
Commission expenses
Share issuance costs
Provision for office relocation expenses
loss on retirement of fixed assets

93,74444,716

1,843,421(156,382)

Gain on reversal of share acquisition rights

106,401

101,333

Total extraordinary income

106,401

101,333–

75,54375,543

Profit before income taxes–
1,949,823

Income taxes - current
Income taxes - deferred

250,928
143,147

568,382

Total income taxes

394,076

658,120

Profit (loss)

1,555,746(788,713)

Profit attributable to non-controlling interests–
1,555,746–(788,713)

Total non-operating expenses
Ordinary profit
Extraordinary income

Extraordinary loss
Impairment loss
Total extraordinary loss

Profit (loss) attributable to owners of parent―7―(130,592)
89,736

Quarterly consolidated statement of comprehensive income for the first nine months of FY 2023

1,555,746(Unit: thousands of yen)
Q3 FY 2023
(from January 1, 2023
to September 30, 2023)(788,713)(21)(1,603)Q3 FY 2022
(from January 1, 2022
to September 30, 2022)
ProfitAccumulated other comprehensive income
Foreign currency translation adjustment
Total other comprehensive income
Comprehensive income(21)(1,603)

1,555,325(790,316)

1,555,325(790,316)––

Comprehensive income attributable toComprehensive income attributable to owners of parent
Comprehensive income attributable to non-controllinginterests―8―

(3) Notes to quarterly consolidated financial statements(Notes to going concern assumptions)None to be reported.
(Notes in case of significant changes to shareholders’ equity)
In the first nine months of FY 2023, the Company issued new shares due to the exercise of some of share acquisition rights
pertaining to the 33rd, 43rd, 44th, 48th, 49th, 52nd, and 53rd warrants. As a result, share capital increased by 51,907 thousand yen andcapital surplus increased by 51,907 thousand yen. The total value of treasury shares increased 772 thousand yen as a result of share
repurchases.
The disposal of treasury shares in response to the request to sell shares by shareholders of less-than-one unit of shares led to adecrease of 28 thousand yen in the total value of treasury shares and a decrease of 6 thousand yen in other capital surplus.
As a result, as of September 30, 2023, consolidated share capital was 17,600,367 thousand yen, capital surplus was 17,575,258
thousand yen, and the total value of treasury shares was 88,898 thousand yen.
(Accounting policy changes)
The Company has applied the “Accounting Standard for Fair Value Measurement” (ASBJ Statement No. 31; June 17, 2021;
hereinafter “Fair Value Measurement Standard”) from the beginning of the first quarter of FY 2023.
In applying the Fair Value Measurement Standard, the Company has followed the transitional treatment prescribed in thetransitional measures provided for in paragraph 27-2 of the Implementation Guidance on Accounting Standard for Fair Value
Measurement and will apply the new accounting standard prescribed by the Fair Value Measurement Standard, prospectively.
The adoption of this accounting standard has no effect on the quarterly consolidated financial statements.
(Significant subsequent events)(Execution of agreement establishing share issuance program and issuance of new shares by way of third-party allotment)
On October 6, 2023 (the “Initial Press Release”), the Company announced that the Company’s Board of Directors, at a meeting
held on the same date, had resolved to enter into an agreement with EVO FUND (the “Allottee”) to set up an equity issue program(the “Agreement to Set up an Equity Issue Program”), and based on the equity issue program established under the Agreement to Set
up an Equity Issue Program (the “Program”), to issue new shares in five tranches (shares issued to the Allottee, whether individuallyor collectively, under the Program are referred to as the “Shares”).
The Company is authorized to issue up to a total of 6,000,000 ordinary shares by way of third-party allotment to the allottees in
the period from 25 October 2023 to 3 April 2024, with ordinary shares to be issued by way of a total of five allotments, from the firstto the fifth allotment.
As at the date of submission, the new shares to be issued by way of third-party allotment are as follows.
(1st allotment) *Note 1
Payment was completed on November 10, 2023
1Class and Numbers Shares Offered

1,200,000 common shares

2

Issue Price

316 yen per share

3

Capital inclusion amount

158 yen per share

4

Total Issue Price

379,200,000 yen

5Increases in Capital Stock and Legal Capital Surplus

189,600,000 yen

6

Deadline for Application

November 10, 2023

7

Due Date of Payment

November 10, 2023

8

Allottee

EVO FUND

―9―

(1)

Development

funds

for

antiviraldrugbrincidofovir (direct expenses)(2)
9Specific uses

Development

funds

for

antiviraldrugbrincidofovir (indirect expenses)(3)

Investment in new in-licensing and M&A forthe purpose of securing long-term growth
opportunities.

(2nd allotment) *Note 1
1Class and Numbers Shares Offered

1,200,000 common shares

2

Issue Price

To be determined *Note 2
The amount to be contributed to capital stock shall behalf the upper limit of an increase in capital stock
under Article 14, Paragraph 1, of the Rules of3

Corporate Accounting (with any fractional amounts

Capital inclusion amountless than one yen resulting from such calculation
rounded up). The increase in the legal surplus shallbe the upper limit of an increase in capital stock lessthe amount of the increase in capital stock.

4

Total Issue Price

To be determined.

5

Increases in Capital Stock and Legal Capital Surplus

To be determined.

6

Allotment resolution date

December 4, 2023 *Note 3

7

Deadline for Application

December 20, 2023

8

Due Date of Payment

December 20, 2023 *Note 3

9Allottee

EVO FUND(1) Development

funds

for

antiviraldrugbrincidofovir (direct expenses)(2) Development funds for antiviral drug
10

Specific uses

brincidofovir (indirect expenses)(3) Investment in new in-licensing and M&A forthe purpose of securing long-term growth
opportunities.

(3rd allotment) *Note 1
1Class and Numbers Shares Offered

1,200,000 common shares

2

Issue Price

To be determined *Note 2
The amount to be contributed to capital stock shall behalf the upper limit of an increase in capital stock
under Article 14, Paragraph 1, of the Rules of3

Corporate Accounting (with any fractional amounts

Capital inclusion amountless than one yen resulting from such calculation
rounded up). The increase in the legal surplus shallbe the upper limit of an increase in capital stock lessthe amount of the increase in capital stock.

―10―

4

Total Issue Price

To be determined.

5

Increases in Capital Stock and Legal Capital Surplus

To be determined.

6

Allotment resolution date

January 22, 2024 *Note 3

7

Deadline for Application

February 7, 2024

8

Due Date of Payment

February 7, 2024 *Note 3

9Allottee

EVO FUND(1) Development

funds

for

antiviraldrugbrincidofovir (direct expenses)(2) Development funds for antiviral drug
10

Specific uses

brincidofovir (indirect expenses)(3) Investment in new in-licensing and M&A forthe purpose of securing long-term growth
opportunities.

(4th allotment) *Note 1
1Class and Numbers Shares Offered

1,200,000 common shares

2

Issue Price

To be determined *Note 2
The amount to be contributed to capital stock shall behalf the upper limit of an increase in capital stock
under Article 14, Paragraph 1, of the Rules of3

Corporate Accounting (with any fractional amounts

Capital inclusion amountless than one yen resulting from such calculation
rounded up). The increase in the legal surplus shallbe the upper limit of an increase in capital stock lessthe amount of the increase in capital stock.

4

Total Issue Price

To be determined.

5

Increases in Capital Stock and Legal Capital Surplus

To be determined.

6

Allotment resolution dateFebruary 29, 2024 *Note 3

7

Deadline for Application

March 18, 2024

8

Due Date of Payment

March 18, 2024 *Note 3

9Allottee

EVO FUND(1) Development

funds

for

antiviraldrugbrincidofovir (direct expenses(2) Development funds for antiviral drug
10

Specific uses

brincidofovir (indirect expenses)(3) Investment in new in-licensing and M&A forthe purpose of securing long-term growth
opportunities.

(5th allotment) *Note 1
1Class and Numbers Shares Offered

1,200,000 common shares

2

Issue Price

To be determined―11―

The amount to be contributed to capital stock shall behalf the upper limit of an increase in capital stock
under Article 14, Paragraph 1, of the Rules of3

Corporate Accounting (with any fractional amounts

Capital inclusion amountless than one yen resulting from such calculation
rounded up). The increase in the legal surplus shall be
the upper limit of an increase in capital stock less theamount of the increase in capital stock.

4

Total Issue Price

To be determined.

5

Increases in Capital Stock and Legal Capital Surplus

To be determined.

6

Allotment resolution date

April 3, 2023 *Note 3

7

Deadline for Application

April 19, 2024

8

Due Date of Payment

April 19, 2024 *Note 3

9Allottee

EVO FUND(1) Development

funds

for

antiviraldrugbrincidofovir (direct expenses(2) Development funds for antiviral drug
10

Specific uses

brincidofovir (indirect expenses)(3) Investment in new in-licensing and M&A forthe purpose of securing long-term growth
opportunities.

*Note 1. The number of shares for each of the 2nd through 5th allotments will range from 1,200,000 shares to 2,500,000 shares, and thetotal will not exceed the 6,000,000 shares stipulated for issuance under the Program. The actual number will be determined by the
Allottee notifying the Company prior to the date of the resolution by the Board of Directors for each allotment (the “Allotment Resolution
Date”).
*Note 2.The issue price for each allotment will be the amount equal to the simple average of the closing price of common shares of theCompany announced by the Tokyo Stock Exchange, Inc. (the “TSE”) during the 10 trading days up to and including the day immediately
preceding the Allotment Resolution Date (rounded off to the first decimal place). (However, if there is no closing price for any of the 10
trading days, the Allotee may decide whether to include such a day in the calculation of the issue price.)*Note 3. The Allotment Resolution Date and the due date of payment may be changed, if agreed upon by the Company and the Allottee.
If such changes occur, the Company will withdraw the securities registration statement allotment and submit a new securities registration
statement.

―12―